To include your compound in the COVID-19 Resource Center, submit it here.

Provenge misses estimates

Dendreon Corp. (NASDAQ:DNDN) reported late Wednesday 2Q11 results below the Street's expectations and withdrew its full-year revenue guidance as a result

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE